1
|
Elleuch M, Ben Bnina M, Loukil F, Hadj Kacem F, Boujelben K, Mnif M, Mnif F, Charfi N, Rekik N, Ben Salah D, Abid M. Metabolic Disorders During Prolactinomas. Metab Syndr Relat Disord 2024; 22:85-89. [PMID: 38232370 DOI: 10.1089/met.2023.0174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2024] Open
Abstract
The metabolic profile during prolactinoma may be subject to significant changes. We aimed to describe the different metabolic aspects in patients monitored for prolactinoma and to study the correlations between the size of the prolactinoma and the metabolic parameters. We conducted a retrospective, descriptive, and analytical study of 77 cases of prolactinomas collected and monitored at the endocrinology and diabetology department of the Hedi Chaker Hospital in Sfax between 2000 and 2017. Our patients were divided into three groups according to the size of their prolactinomas. Statistical correlations were sought between tumor size and clinical and biological parameters. The mean age of our patients was 38.3 ± 14.2 years. They were divided into 51 women (66.2%) and 26 men (33.7%). Pituitary tumor syndrome was the most common circumstance of discovery in our population (62.3%). The clinical examination revealed an average waist circumference of 95.71 cm. Android fat distribution was observed in 25 women (49%) and 12 men (46.1%). A statistically significant positive correlation was objectified between waist circumference and tumor size (r = 0.29 and P = 0.019). The average body mass index was 28.08 kg/m2. Obesity was noted in 56 cases (72.7%). Glucose tolerance disorders and hypertriglyceridemia were also more evident each time prolactinoma size increased in contrast to the level of high-density lipoprotein cholesterol which decreased with adenoma size. Our study highlighted the metabolic and hormonal repercussions of prolactinomas. Metabolic syndrome was more common in patients with larger prolactinoma. These results should guide the initial assessment and therapeutic management of prolactin adenomas.
Collapse
Affiliation(s)
- Mouna Elleuch
- Department of Endocrinolgy Diabetology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia
| | - Molka Ben Bnina
- Department of Endocrinolgy Diabetology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia
| | - Fatma Loukil
- Department of Endocrinolgy Diabetology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia
| | - Faten Hadj Kacem
- Department of Endocrinolgy Diabetology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia
| | - Khouloud Boujelben
- Department of Endocrinolgy Diabetology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia
| | - Mouna Mnif
- Department of Endocrinolgy Diabetology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia
| | - Fatma Mnif
- Department of Endocrinolgy Diabetology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia
| | - Nadia Charfi
- Department of Endocrinolgy Diabetology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia
| | - Nabila Rekik
- Department of Endocrinolgy Diabetology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia
| | - Dhouha Ben Salah
- Department of Endocrinolgy Diabetology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia
| | - Mohamed Abid
- Department of Endocrinolgy Diabetology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia
| |
Collapse
|